FALLOPIAN TUBE CANCER

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian, fallopian tube, or primary peritoneal cancer that does not have a BRCA mutation. Over 1,300 pa…

This early-stage trial tested a new personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer. All participants had completed standard chemotherapy and were in complete remission. The main goal was to check the treatment's sa…

This phase 2 study tested a drug called mirvetuximab soravtansine in 79 people with recurrent ovarian, peritoneal, or fallopian tube cancer that had high levels of a protein called folate receptor-alpha. The cancer had come back after platinum-based chemotherapy but was still sen…

This study tested a new drug called RC88 in 43 women whose ovarian, fallopian tube, or peritoneal cancer had stopped responding to platinum-based chemotherapy. The goal was to see if RC88 could shrink tumors and how safe it was. Participants had already tried at least three other…

This study tested an experimental drug called ZN-c3, given alone or with another drug (niraparib), in 117 people with ovarian cancer that stopped responding to platinum-based chemotherapy. The goal was to find safe doses and see if the treatment could shrink tumors or slow the di…

This study tested whether the immunotherapy drug pembrolizumab could help keep ovarian cancer from growing after initial chemotherapy. Twenty women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer received weekly paclitaxel followed by pembrolizumab as mainte…

This early-phase trial tested an experimental drug called SL-172154 combined with either standard chemotherapy or a targeted therapy in 86 people with ovarian cancer that stopped responding to platinum-based treatments. The main goals were to check safety and find the best dose. …

This study tested whether adding the drug aprepitant to standard anti-nausea medicines could better prevent nausea and vomiting caused by chemotherapy in 143 women with gynecologic cancers like ovarian or cervical cancer. Participants received either the three-drug combo or a pla…

This study looked at whether testing ovarian cancer tumors for BRCA gene mutations right in the doctor's office is practical and helpful. 200 patients with a specific type of ovarian cancer provided tumor samples for genetic testing. The goal was to see if this upfront testing co…

This study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how their tumor's genetic makeup relates to their disease. Researchers collected tumor samples and medical data to find links between specific gene changes and how long patients st…

This study aimed to create a blood test that could predict when ovarian, peritoneal, or fallopian tube cancer might come back. Researchers looked for specific protein patterns, called a 'fingerprint,' in the blood of 119 women whose cancer was in remission. Participants had regul…

This study followed 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking niraparib as a maintenance treatment to keep their cancer from coming back. Researchers observed how well patients tolerated the drug in everyday clinical practice, without g…

This study reviewed medical records of 51 women with ovarian, fallopian tube, or primary peritoneal cancer who received the drug rucaparib in regular clinical practice in Spain. Researchers looked at patient history, side effects, dosing, and how well the drug controlled the canc…

This study tested a digital tool (a chatbot) to help cancer survivors learn about genetic testing for hereditary cancer risk. 50 adults who had certain cancers (like breast, ovarian, or prostate) took part. The goal was to see if the chatbot was easy to use and if it helped more …